Illustrative global need: 0 people since opening · not a live count
Independent presentation based on public information. Not an official publication, affiliation, or endorsement by any organization cited.
A breath should not depend on where you are born.
Medical oxygen is essential care. Getting it to a bedside takes a whole working system.
Explore the scale of need, the gaps in access, and the investment that could help close them. Published evidence—not a live patient monitor or a clinical guide.
Scroll to continue
Oxygen is essential treatment. Access takes infrastructure.
When people hear "oxygen access," they think pneumonia. But oxygen therapy is needed across 20 different conditions, from heart attacks to car crashes to premature births. Without it, modern medicine can't function.
Source: Lancet Commission (2025), Tables 1–2. Selected conditions; 2021 estimates, millions of people. Long-term COPD is shown separately from acute conditions. This is not an exhaustive ranking; surgery and COVID-19 are not shown.
Patient counts describe need, not the number of people receiving adequate oxygen therapy.
A lifesaving investment. A gap we can close.
The opportunity is practical: identify the gap, build dependable infrastructure, and sustain the supply chain. Equipment matters, but so do maintenance, trained teams, and reliable power.
The tools already exist. Pulse oximeters help detect low blood oxygen, while oxygen sources and delivery equipment support treatment. Purchase prices alone do not capture the full cost of keeping a system working.
💰$168Estimated cost per DALY avertedDALY = a year of healthy life lost
📈$21Projected benefit per $1 investedEconomic benefit, not a cash return
🫁860KProjected lives saved by 2030With the full US$4 billion investment
👶331KProjected under-5 lives savedIncluded in the total by 2030
Source: GO₂AL Strategic Framework & Investment Case 2025–2030. Lancet Commission on Medical Oxygen Security, Feb 2025.
Access is more than availability.
Regional estimates below describe safe, appropriate therapy for acute medical conditions in low- and middle-income countries. They exclude surgical and long-term needs.
Coverage gap ↓
Adequate therapy Coverage gap
Source: Lancet Commission, Figure 3 C–H (2025). Rounded regional estimates, not a current country ranking. These patient-based percentages differ from the volume-based PATH globe.
What is moving forward in 2026?
26 FEBRUARY 2026 · PATH / UNITAID
Test systems that last
The four-year INNOVATE initiative will test oxygen technologies and delivery models in India, Kenya, Malawi, Nigeria, and Senegal. These are planned pilots—not measured population-wide outcomes.
A regional respiratory-equipment manual addresses installation skills and maintenance needs in South-East Asia. It adds practical guidance, not a replacement global oxygen-needs estimate.
Public sources reviewed September 10, 2026. GO₂AL’s resource library continues to list the 2025–2030 investment case; newer guidance does not make its projections observed results.
Not yet achievedModeled benefits, not a progress tracker
$0Additional donor investment, 2025–2030
$0$4 Billion
0Projected lives saved by 2030
0Additional patients reached by 2030
-Cost per DALY
Projected economic benefit: $21 per $1 invested
Illustrative slider, not a forecast: values between zero and the published US$4 billion endpoint are linearly scaled. Actual results depend on where and how funds are invested.
Understand the gap. Explore what could change.
Read the evidence, explore the country data, and share what you learn. This independent presentation does not collect donations or represent the organizations whose work it cites.
Reading this story: Sources reviewed September 10, 2026. Published estimates and projections are not observed real-time activity. The elapsed-time counter is illustrative. The investment slider linearly scales GO₂AL’s published endpoint; intermediate positions are not validated forecasts. The dot sequence explicitly changes from worldwide people to an LMIC acute-care percentage denominator. This story uses patient-based estimates; the linked globe uses a separate PATH model of annual oxygen volume. Their percentages are not interchangeable. No patient quotation or consent claim is made here.
1
Lancet Global Health Commission on medical oxygen security. Graham HR et al. Lancet Global Health 2025;13:e528–84. Open-access report. Used for: Annual need (2021 estimates), acute-care coverage, regional cascade (Figure 3), and selected condition counts (Tables 1–2). Estimates have uncertainty; rounded headline values are not precise counts.
2
GO₂AL Strategic Framework & Investment Case 2025–2030. Global Oxygen Alliance, 14 Oct 2024. Investment case Used for: US$4 billion additional investment; 860,000 projected lives saved by 2030, including 331,000 children under five; 24 million additional patients; US$168 per DALY averted; US$21 in projected economic benefit per dollar.
3
WHO respiratory-equipment manual. Published August 17, 2026. Publication overview. Used for the maintenance update, not global burden numbers.
4
PATH / Unitaid INNOVATE announcement. February 26, 2026. Public announcement. Planned technology and delivery-model pilots; no achieved outcomes inferred.
5
PATH: Breath of life. April 2026. Video and source page. Optional real-world context, hosted by its publisher; not a production partner of this presentation.